alendronate- alendronate sodium tablet
virtus pharmaceuticals - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronic acid 35 mg - alendronate sodium tablets, usp are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, alendronate sodium tablets, usp increase bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [see clinical studies (14.1).] alendronate sodium tablets, usp are indicated for the prevention of postmenopausal osteoporosis [see clinical studies (14.2)] . alendronate sodium tablets, usp are indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.3)] . alendronate sodium tablets, usp are indicat
alendronate- alendronate sodium tablet
nucare pharmaceuticals,inc. - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronic acid 35 mg - alendronate sodium tablets, usp are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, alendronate sodium tablets, usp increase bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [see clinical studies (14.1).] alendronate sodium tablets, usp are indicated for the prevention of postmenopausal osteoporosis [see clinical studies (14.2)] . alendronate sodium tablets, usp are indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.3)] . alendronate sodium tablets, usp are indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density [see clinical studie
alendronate- alendronate sodium tablet
hangzhou minsheng binjiang pharmaceutical co., ltd. - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronic acid 35 mg - alendronate sodium tablets, usp are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, alendronate sodium tablets, usp increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [see clinical studies (14.1).] alendronate sodium tablets, usp are indicated for the prevention of postmenopausal osteoporosis [see clinical studies (14.2)] . alendronate sodium tablets, usp are indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.3)] . alendronate sodium tablets, usp are indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucoc
alendronate sodium tablet
rebel distributors corp - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronic acid 35 mg - alendronate sodium tablets, usp are indicated for: - treatment and prevention of osteoporosis in postmenopausal women for the treatment of osteoporosis, alendronate sodium tablets, usp increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures). osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture. (see clinical pharmacology, pharmacodynamics.) for the prevention of osteoporosis, alendronate sodium tablets, usp may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. bone loss is particularly rapid in postmenopausal women younger than age 60. risk factors often associated with the development of postmenopausal osteoporosis include early menopause; modera
alendronate sodium tablet
dispensing solutions inc. - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronic acid 70 mg - alendronate sodium tablets, usp are indicated for: - treatment and prevention of osteoporosis in postmenopausal women for the treatment of osteoporosis, alendronate sodium tablets, usp increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures). osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture. (see clinical pharmacology, pharmacodynamics.) for the prevention of osteoporosis, alendronate sodium tablets, usp may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. bone loss is particularly rapid in postmenopausal women younger than age 60. risk factors often associated with the development of postmenopausal osteoporosis include early menopause; modera
alendronate sodium tablet
aidarex pharmaceuticals llc - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronic acid 70 mg - alendronate sodium tablets usp are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, alendronate sodium tablets usp increase bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures) [see clinical studies (14.1) ]. alendronate sodium tablets usp are indicated for the prevention of postmenopausal osteoporosis [see clinical studies (14.2) ]. alendronate sodium tablets usp are indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.3) ]. alendronate sodium tablets usp are indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density [see clinical studies (14.4) ]. alendronate sodium tablets usp are indicated for the treatment of paget’s disease of bone in men and women. treatment is indicated in patients with paget's di
alendronate teva 70 mg
teva pharmaceutical industries ltd, israel - alendronic acid as sodium - tablets - alendronic acid as sodium 70 mg - alendronic acid - alendronic acid - for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip and spine (vertebral compression fractures).treatment to increase bone mass in men with osteoporosis.
alendronate teva 70 mg
teva pharmaceutical industries ltd, israel - alendronic acid as sodium - tablets - alendronic acid as sodium 70 mg - alendronic acid - alendronic acid - for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip and spine (vertebral compression fractures).treatment to increase bone mass in men with osteoporosis.
alendronate sodium tablet
nucare pharmaceuticals,inc. - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronate sodium tablets are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, alendronate sodium tablets increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [see clinical studies (14.1).] alendronate sodium tablets are indicated for the prevention of postmenopausal osteoporosis [see clinical studies (14.2)] . alendronate sodium tablets are indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.3)] . alendronate sodium tablets are indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density [see clinical studies (14.4)] . al
alendronate sodium solution
hikma pharmaceuticals usa inc. - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronate sodium is indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, alendronate increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures) [see clinical studies ( 14.1) ] . alendronate sodium is indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies ( 14.3) ] . the optimal duration of use has not been determined. the safety and effectiveness of alendronate for the treatment of osteoporosis are based on clinical data of four years duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. alendronate sodium is contraindicated in patients with the following conditions: risk summary: availabl